Morningstar

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

Provided by Dow Jones

By Josh Beckerman 




  UCB agreed to buy Neurona Therapeutics for up to $1.15 billion, a deal that would add potential epilepsy drug NRTX-1001 to the Belgian company's portfolio. 



  The agreement includes $650 million upfront and up to $500 million in potential future milestone payments. 



  UCB expects to close the transaction by the end of the second quarter. 



  Column Group, a longtime Neurona investor, led a $23.5 million Series A funding announced in late 2015. Other investors have included Fidelity Management & Research Co., UCB Ventures and Alexandria Venture Investments. 



  In December, South San Francisco-based Neurona presented results from ongoing Phase 1/2 trials evaluating NRTX-1001, a one-time, allogeneic inhibitory interneuron cell therapy for drug-resistant mesial temporal lobe epilepsy. The company said it continued to see durable seizure reduction from a single administration in most subjects. 





  Write to Josh Beckerman at josh.beckerman@wsj.com 





  (END) Dow Jones Newswires



  April 17, 2026 16:26 ET (20:26 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
Our Best Investment Portfolio Examples for Savers and Retirees
 
This collection of Morningstar model portfolios from Christine Benz can help investors build portfolios to reach their financial goals. 
 
 
Christine Benz and Valentina Djeljosevic 
 
 
 
The Surprising Stocks Beating the Market in 2026
 
Companies spending on dividends and buybacks are winning this year. 
 
 
Dan Lefkovitz 
 
 
 
September Stock Market Outlook: How to Position Your Portfolio During a Risky Stage
 
Excluding just seven stocks from our valuation, the remaining market is trading at fair value. 
 
 
David Sekera, CFA 
 
 
 
The 7 Best Dividend Aristocrats to Buy Now for the Long Term 
 
How to avoid the dividend aristocrat trap and find reliable income stocks. 
 
 
Susan Dziubinski 
 
 
 
2 Tech Stocks to Avoid in Case Stocks Sell Off
 
The technology sector has historically underperformed in September. Here are two overvalued stocks to avoid.  
 
 
David Sekera, CFA, Susan Dziubinski, and Jess Bebel 
 
 
 
 

			Sponsor Center